Clinical phenotypes and genetic features of hereditary transthyretin amyloidosis patients in China

被引:9
|
作者
He, Xinyue [1 ]
Tian, Zhuang [1 ,2 ]
Guan, Hongzhi [3 ]
Zhang, Shuyang [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Cardiol, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Int Med Serv, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Neurol, Beijing, Peoples R China
关键词
Transthyretin amyloidosis; Rare disease; Hereditary; Chinese; VITREOUS AMYLOIDOSIS; POLYNEUROPATHY; MUTATION; GLY83ARG;
D O I
10.1186/s13023-022-02481-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Hereditary transthyretin amyloidosis (hATTR) is a progressive and fatal disease with heterogenous clinical presentations, limited diagnosis and poor prognosis. This retrospective analysis study aimed to report the genotypes and phenotypes of herediary transthyretin amyloidosis (hATTR) in Chinese through a systematic review of published literature. Methods The systematic review included structured searches of peer-reviewed literature published from 2007 to 2020 of following online reference databases: PubMed, Web of Science and the literature database in China. Extracted data included sample size, personal information (sex, age, natural course, family history), mutation type, clinical milestones and reason of death. Results We described 126 Chinese patients with hereditary transthyretin amyloidosis identified through a systematic review of 30 studies. The most common genotype in the Chinese population was Gly83Arg (25, 19.8%), which most likely presented visual and neurological abnormalities without reported death. The second and third most common genotypes were Val30Met (20, 15.9%) and Val30Ala (10, 7.9%). Peripheral neurological manifestations (91, 72%) were dominant in 126 patients. The followed manifestation was autonomic neurological abnormalities (73, 58%). Half of the cases were reported to have visual disorders, and nearly one-third of the cases presented cardiac abnormalities. Among all 126 reported patients, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. In addition. Chinese patients were mostly early onset, with age of onset at 41.8 (SD: 8.9) years, and the median time from onset to death was 7.5 [IQR: 5.3] years. Patients with cardiac involvement had a shorter survival duration (log Rank (Mantel-Cox), chi(2) = 26.885, P < 0.001). Conclusions This study focused on 126 Chinese hATTR patients obtained from a literature review. A total of 26 kinds of TTR mutations were found and the most common one was Gly83Arg. As for phenotype, 46.03% were classified as neurological type, 30.16% as mixed type and only 2.38% as cardiac type. Chinese hATTR patients were mostly early onset (AO 41.8 years), and the median time from onset to death was 7.5 years.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis
    Coelho, Teresa
    Maurer, Mathew S.
    Suhr, Ole B.
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (01) : 63 - 76
  • [22] Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
    Hsu, Hui-Ching
    Liao, Ming-Feng
    Hsu, Jung-Lung
    Lee, Yun-Lin
    Ro, Long-Sun
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2018, (136):
  • [23] Loss of gastric interstitial cells of Cajal in patients with hereditary transthyretin amyloidosis
    Wixner, Jonas
    Obayashi, Konen
    Ando, Yukio
    Karling, Pontus
    Anan, Intissar
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2013, 20 (02): : 99 - 106
  • [24] Hereditary transthyretin amyloidosis overview
    Manganelli, Fiore
    Fabrizi, Gian Maria
    Luigetti, Marco
    Mandich, Paola
    Mazzeo, Anna
    Pareyson, Davide
    NEUROLOGICAL SCIENCES, 2022, 43 (Suppl 2) : 595 - 604
  • [25] Hereditary transthyretin amyloidosis (ATTRv)
    Triposkiadis, Filippos
    Briasoulis, Alexandros
    Starling, Randall C.
    Magouliotis, Dimitrios E.
    Kourek, Christos
    Zakynthinos, George E.
    Iliodromitis, Efstathios K.
    Paraskevaidis, Ioannis
    Xanthopoulos, Andrew
    CURRENT PROBLEMS IN CARDIOLOGY, 2025, 50 (04)
  • [26] A compound score to screen patients with hereditary transthyretin amyloidosis
    Tozza, Stefano
    Severi, Daniele
    Spina, Emanuele
    Di Paolantonio, Andrea
    Iovino, Aniello
    Guglielmino, Valeria
    Aruta, Francesco
    Nolano, Maria
    Sabatelli, Mario
    Santoro, Lucio
    Luigetti, Marco
    Manganelli, Fiore
    JOURNAL OF NEUROLOGY, 2022, 269 (08) : 4281 - 4287
  • [27] Clinical characteristics in patients with hereditary amyloidosis with Glu54Gln transthyretin identified in the Romanian population
    Jercan, Andreea
    Ene, Amalia
    Jurcut, Ruxandra
    Draghici, Mirela
    Badelita, Sorina
    Dragomir, Mihaela
    Dobrea, Camelia
    Popescu, Monica
    Jardan, Dumitru
    Stoica, Emanuel
    Iacob, Speranta
    Codita, Ionela
    Stan, Claudiu
    Coriu, Daniel
    ORPHANET JOURNAL OF RARE DISEASES, 2020, 15 (01)
  • [28] Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
    Coelho, Teresa
    Yarlas, Aaron
    Waddington-Cruz, Marcia
    White, Michelle K.
    Kessler, Asia Sikora
    Lovley, Andrew
    Pollock, Michael
    Guthrie, Spencer
    Ackermann, Elizabeth J.
    Hughes, Steven G.
    Karam, Chafic
    Khella, Sami
    Gertz, Morie
    Merlini, Giampaolo
    Obici, Laura
    Schmidt, Hartmut H.
    Polydefkis, Michael
    Dyck, P. James B.
    Brannagan, Thomas H., III
    Conceicao, Isabel
    Benson, Merrill D.
    Berk, John L.
    JOURNAL OF NEUROLOGY, 2020, 267 (04) : 1070 - 1079
  • [29] The Gly103Arg variant in hereditary transthyretin amyloidosis
    Xiong, Yihan
    Qu, Gongcheng
    Lu, Xiaoyu
    Chang, Xin
    Zhang, Miaoping
    Liang, Jiantang
    Lin, Kexing
    Zhao, Xiaoman
    Fu, Xuejun
    Huang, Ying
    Xu, Qianhui
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [30] Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
    Teresa Coelho
    Aaron Yarlas
    Marcia Waddington-Cruz
    Michelle K. White
    Asia Sikora Kessler
    Andrew Lovley
    Michael Pollock
    Spencer Guthrie
    Elizabeth J. Ackermann
    Steven G. Hughes
    Chafic Karam
    Sami Khella
    Morie Gertz
    Giampaolo Merlini
    Laura Obici
    Hartmut H. Schmidt
    Michael Polydefkis
    P. James B. Dyck
    Thomas H. Brannagan III
    Isabel Conceição
    Merrill D. Benson
    John L. Berk
    Journal of Neurology, 2020, 267 : 1070 - 1079